A multicentre retrospective study. Objective. To study the effectiveness and safety of using a prothrombin complex concentrate in postpartum haemorrhages. Materials and methods. We distributed the questionnaires that contained questions about the risk factors of developing postpartum haemorrhage (PH), the volume of blood loss and methods of its diagnosis, the volume of transfusion of fresh frozen plasma, the use of blood clotting factor concentrates, complications during the postpartum period. Results. Assessment of risk factors for developing PH has shown that three main risk factors were preeclampsia (arterial hypertension) during pregnancy (25.6%), placenta previa (18.6%) and premature rupture of membranes (15.3%). The use of Prothromplex 600 in complex therapy of postpartum haemorrhage permitted to decrease the number of parturient women with transfusion of fresh frozen plasma (FFP) on average by 40% and the number of parturient women with transfusion of FFP 12–15 ml/kg on average by 44%. No significant difference in the use of FFP 20–30 ml/kg has been noted, which is confirmed by the absence of a statistically significant difference in the corresponding rates between the groups. Conclusion. The use of Prothromplex in complex therapy of postpartum haemorrhage permits to earlier start haemostatic therapy, which, in its turn, decreases a further need for transfusion of fresh frozen plasma, reducing the risk of development of TRALI and TACO syndromes.